13. Remission induction in acute myeloid leukemia

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ananth Shankar

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch13

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Shankar, A. (2013) Remission induction in acute myeloid leukemia, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch13

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. University College London Hospitals NHS Foundation Trust, London, UK

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309



  • acute myeloid leukemia (AML);
  • Berlin Frankfurt Münster (BFM) 93 trial;
  • Children's Cancer Study Group (CCSG);
  • daunorubicin (DNR);
  • MRC AML 10 trial;
  • MRD;
  • remission induction


This chapter provides a summary of previous studies and four new studies. The improved survival outcome in children with acute myeloid leukemia (AML) can be linked to the progress made in the induction regimens used to improve remission rates. The Children's Cancer Study Group (CCSG) trial CCG 213 that was conducted between January 1986 and February 1989 compared a standard remission induction regimen of cytosine arabinoside (ARAC) and daunorubicin (DNR) with a five-drug DCTER regimen comprising ARAC, DNR, etoposide (VP-16), dexamethasone (DEX), and thioguanine (TG). Remission success was similar with both regimens. The chapter also talks about the MRC AML 10 trial and the Berlin Frankfurt Münster (BFM) 93 trial. The objectives, study design, statistics, results, and toxicity of the new studies are also discussed.